reports
- Jonathan Moreland
CMI CUMMINS INC.
NCR NCR CORPORATION
UNH UNITEDHEALTH GROUP INCORPORATED
OEC ORION ENGINEERED CARBONS SA
LGND LIGAND PHARMACEUTICALS INCORPORATED
JRVR JAMES RIVER GROUP HOLDINGS LTD
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HUM HUMANA INC.
GLP GLOBAL PARTNERS LP
BRKR BRUKER CORPORATION
ASYS AMTECH SYSTEMS INC.
ERII ENERGY RECOVERY INC.
ELY CALLAWAY GOLF COMPANY
HTLD HEARTLAND EXPRESS INC.
VSH VISHAY INTERTECHNOLOGY INC.
GCBC GREENE COUNTY BANCORP INC.
WINA WINMARK CORP.
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
NNBR NN
LILA INC.
COLD LIBERTY LATIN AMERICA A
EAF AMERICOLD REALTY TRUST
ULBI GRAFTECH INTERNATIONAL
MIDD ULTRALIFE
ENR THE MIDDLEBY CORPORATION
RPAY EDGEWELL PERSONAL CARE COMPANY
PRG REPAY HOLDINGS (A)
LESL PROG HOLDINGS
GRNT INC.
ALKT LESLIES
CVRX GRANIT SKOPKE
MINM ALKAMI TECHNOLOGY
MYO INC.
FLNC CVRX
DCGO INC.
STGW MINIM
OGN INC.
PFHC MYOMO
RXO_w FLUENCE ENERGY INC
OABI DOCGO INC
WEST STAGWELL INC
SRPT ORGANON & CO
FTK PROFRAC HLDG CORP
TXO RXO INC
AESI OMNIAB INC
FINS WESTROCK COFFEE COMPANY LLC
SAREPTA THERAPEUTICS
INC.
FLOTEK INDUSTRIES INC.
MORNINGSTAR PARTNERS
L.P.
ATLAS ENERGY SOLUTIONS INC.
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
- Jonathan Moreland
UNH UNITEDHEALTH GROUP INCORPORATED
PEB PEBBLEBROOK HOTEL TRUST
JRVR JAMES RIVER GROUP HOLDINGS LTD
HUM HUMANA INC.
GLP GLOBAL PARTNERS LP
FISV FISERV INC.
ASYS AMTECH SYSTEMS INC.
HTLD HEARTLAND EXPRESS INC.
EB EVENTBRITE
MIDD THE MIDDLEBY CORPORATION
RPAY REPAY HOLDINGS (A)
DLHC DALEIGH HOLDINGS CORP
GRNT GRANIT SKOPKE
ALKT ALKAMI TECHNOLOGY
PFHC INC.
RXO_w PROFRAC HLDG CORP
WEST RXO INC
FTK WESTROCK COFFEE COMPANY LLC
FG FLOTEK INDUSTRIES INC.
AESI F AND G ANNUITIES AND LIFE
FINS INC.
LBTYK ATLAS ENERGY SOLUTIONS INC.
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
LIBERTY GLOBAL LTD.
Korro to Participate in Upcoming Investor Conferences
Korro to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Wednesday, May 21, 2025, at 2:35 p.m. ET. Jefferies Global Healthcare Conference Dr. Aiyar and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will present on Wednesday, June 4, 2025, at 9:55 ...
- Jonathan Moreland
OEC ORION ENGINEERED CARBONS SA
LTRX LANTRONIX INC.
LGND LIGAND PHARMACEUTICALS INCORPORATED
NEWT NEWTEK BUSINESS SERVICES INC.
HTLD HEARTLAND EXPRESS INC.
UEIC UNIVERSAL ELECTRONICS INC.
VSH VISHAY INTERTECHNOLOGY INC.
FLL FULL HOUSE RESORTS INC.
FLWS
NINE 1-800-FLOWERS.COM CL A
CNX NINE ENERGY SERVICE INC
A2H9KJ CONSOL ENERGY INC.
TCPC NEO PERFORMANCE MATERIAL
MIDD BLACKROCK TCP CAPITAL CORP.
ENR THE MIDDLEBY CORPORATION
PHAT EDGEWELL PERSONAL CARE COMPANY
DLHC PHATHOM PHARMACEUTICALS
MINM DALEIGH HOLDINGS CORP
STGW MINIM
NVCT INC.
PFHC STAGWELL INC
RXO_w NUVECTIS PHARMA INC
FTK PROFRAC HLDG CORP
NCDL RXO INC
DMA FLOTEK INDUSTRIES INC.
GF NUVEEN CHURCHILL DIRECT LENDING CORP
IAE DESTRA MULTI ALTERNATIVE FUND
THRM THE NEW GERMANY FUND
AESI INC.
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
SOLTA MEDICAL, INC
ATLAS ENERGY SOLUTIONS INC.
Korro Reports First Quarter 2025 Financial Results and Provides Busine...
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates —Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025 —Streamlining operations and focusing on delivering potential value generating program milestones, with workforce reduction of approximately 20% and cost reductions expected to extend cash runway into 2027 —Second development candidate expected to be announced in 2025 —Ended first quarter 2025 with $139.0 million in cash, cash equivalents and marketable securitie...
Genelux Corporation Reports First Quarter 2025 Financial Results and P...
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates. “The first quarter of 2025 has been highly productive and sets a strong foundation for the year ahead. We are well positioned to advance Olvi-Vec across multiple high-need cancer indications, with encouraging regulatory feedback from the FDA on our OnPrime Phase ...
Genelux Corporation to Participate in a Fireside Chat at the Citizens ...
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that , President, CEO and Chairman of the Board, and , CFO, will discuss clinical-stage programs and upcoming milestones in a fireside chat at the Citizens Life Sciences Conference taking place May 7-8, 2025, in New York. The conversation with Biotech Equity Research Managing Director, Silvan Tuerkcan, PhD, is scheduled to begin at 1:30 p.m. ET on Thursd...
- Wedbush Research
ZION ZIONS BANCORPORATION N.A.
WTFC WINTRUST FINANCIAL CORPORATION
WBS WEBSTER FINANCIAL CORPORATION
WAL WESTERN ALLIANCE BANCORP
VLY VALLEY NATIONAL BANCORP
TCBI TEXAS CAPITAL BANCSHARES INC.
RF REGIONS FINANCIAL CORPORATION
PPBI PACIFIC PREMIER BANCORP INC.
PB PROSPERITY BANCSHARES INC.(R)
NYCB NEW YORK COMMUNITY BANCORP INC.
KEY KEYCORP
HMST HOMESTREET INC.
HBAN HUNTINGTON BANCSHARES INCORPORATED
HAFC HANMI FINANCIAL CORPORATION
FITB FIFTH THIRD BANCORP
FHN FIRST HORIZON CORPORATION
FFWM FIRST FOUNDATION
EWBC EAST WEST BANCORP INC.
CVBF CVB FINANCIAL CORP.
CUBI CUSTOMERS BANCORP INC.
COLB COLUMBIA BANKING SYSTEM INC.
CFG CITIZENS FINANCIAL GROUP INC.
CATY CATHAY GENERAL BANCORP
BKU BANKUNITED INC.
BANC BANC OF CALIFORNIA INCORPORATED
CFR CULLEN/FROST BANKERS INC.
BOKF BOK FINANCIAL CORPORATION
CMA COMERICA INCORPORATED
SLM SLM CORP
HOPE HOPE BANCORP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
AX AXOS FINANCIAL INC.
LC LENDINGCLUB CORP
AFRM AFFIRM HOLDINGS
BUR BURFORD CAPITAL
UPST UPSTART HOLDINGS
SOFI SOFI TECHNOLOGIES INC
PGY PAGAYA TECHNOLOGIES LTD
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief...
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of Oliver Dolan to Principal Accounting Officer CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announ...
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financia...
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update – Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer – – Matt Pulisic joined the company as its new Chief Financial Officer – – Closing of $10.5 Million Underwritten Offering of Common Stock – – $30.9 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif....
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Of...
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an offering price of $3.50 per share. The gross proceeds to Genelux from the offering are expected to be $10.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux. Titan Partners G...
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of ...
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer – Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all target lesions, with one participant achieving a tumor reduction of approximately 79%. – Additionally, three participants, including one individual with three prior lines of treatment, achieved stable disease at lower dose cohorts, with tumor size reductions ra...
Genelux Announces Alignment with FDA on Key Elements of the Approval P...
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease - U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval - WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Genelux has concluded a productive Type D meeting with the U.S. Food and Drug Administration (FDA) for Olvi-Vec in the treatment of platinum resistant/r...
Korro Reports Full Year 2024 Financial Results and Provides Business U...
Korro Reports Full Year 2024 Financial Results and Provides Business Updates —Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 —U.S. Food and Drug Administration (FDA) Granted Orphan Drug Designation to KRRO-110 for the treatment of AATD —Executing 3-2-1 strategy through end of 2027 with the goal of establishing three clinical-stage development programs, targeting two tissue types with a single RNA-editing platform; Second development candidate expected to ...
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 An...
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). “Receiving orphan drug designation from the ...
Korro to Present at the TD Cowen 45th Annual Health Care Conference
Korro to Present at the TD Cowen 45th Annual Health Care Conference CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. ET at the Boston Marriott Copley Place. Todd Chappell, Chief Operating Officer, will als...
Genelux Corporation Announces New Chief Financial Officer
Genelux Corporation Announces New Chief Financial Officer WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025. "I am very pleased to welcome Matt as our new Chief Financial Officer. Matt’s financial acumen, strategic mindset and proven leadership abilities are an ideal fit for Genelux,” said Thomas Zindrick, President, CEO and Chairman of the Board. “His unique combination of financial expertis...
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a...
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update KRRO-110 is the first product candidate from Korro’s proprietary RNA editing OPERATM platformInterim readout from REWRITE expected in the second half of 2025 Korro to advance additional pipeline programs towards clinical development CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing R...
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 3:45 p.m. PT (6:45 p.m. ET) at the Westin St. Francis in San Francisco. Vineet Agarwal, Chief ...
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwr...
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that , President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024. Biotech Equity Research Analyst, Emily Bodnar, will moderate the HCW@Home session which is scheduled to begin at 11:00 a.m. ET. The discussion will focus on the company’s clinical program of its lead candidate, Olvi-Vec, including its o...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.